Every S-1 that Avalon GloboCare Corp. (ALBT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-1 covers the registration statement a company files to sell shares publicly, so if you follow ALBT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALBT filings page.
Change Agents Corporation is registering 35,569,258 shares of common stock for resale by existing holders, including up to 33,333,333 Put Shares issuable to Hudson Global Ventures at a fixed purchase price of $0.30 per share and 925,925 warrant shares at $0.01 per share.
The company operates two segments: an AI software business (the Catch-Up agentic short-form video platform and Beacon Generative Engine Optimization search tool) and a consumer health segment distributing the Keto Air ketosis breathalyzer in North America. It has also formed Autonomous Air Defense LLC to explore AI-enabled drone surveillance and counter‑UAS technologies.
Change Agents reports early-stage operations, no sustainable revenue, and significant losses, with net losses from continuing operations of approximately $4.48 million for the quarter ended March 31, 2026 and $17.5 million for 2025, and an accumulated deficit of about $110.4 million$200,000 versus an estimated $5,000,000 needed to fund 12 months of operations, and outstanding indebtedness was about $2.1 million, including an $825,000 secured business loan. The company warns of substantial doubt about its ability to continue as a going concern and notes Nasdaq minimum bid‑price non‑compliance.
Avalon GloboCare Corp., a Delaware company listed on Nasdaq as “ALBT,” is registering a primary offering of common stock and pre-funded warrants, each sold with accompanying common warrants, plus placement agent warrants. The common warrants become exercisable either after stockholder approval of the warrant shares or immediately if specified Nasdaq “Pricing Conditions” are met, and expire five years after they first become exercisable.
Avalon has pivoted from biotech to a technology-focused model with two segments: an Agentic AI software business (including its Catch-Up short-form video platform and Beacon AI search-visibility product) and a consumer health technology business distributing the Keto Air ketosis breathalyzer in North America. The company reports substantial net losses, an accumulated deficit over $110 million, limited cash, and outstanding indebtedness, leading to substantial doubt about its ability to continue as a going concern absent additional financing.
Avalon also discloses a Nasdaq notice for failing the $1.00 minimum bid price requirement, with an initial 180-day cure period to October 12, 2026, potential further grace periods, and possible delisting if compliance is not regained. The filing highlights significant potential dilution from outstanding preferred stock, options, warrants, and new securities in this offering, as well as legal, regulatory, and commercialization risks around its AI and Keto Air products.
Avalon GloboCare Corp. has filed a resale registration covering up to 19,436,278 shares of common stock for existing investors. These consist of 490,197 already-issued shares plus shares underlying pre-funded warrants, Series A-1 and A-2 warrants, and placement agent warrants issued in a February 2026 private placement.
The company will not receive proceeds from investors’ resale of these shares, but could receive about $6.7 million if 18,946,081 warrant shares are fully exercised for cash. Shares outstanding were 8,323,609 as of April 8, 2026 and would be 27,759,887 if all registered warrants are exercised. The filing also highlights a history of substantial losses, a $105.9 million accumulated deficit, minimal cash, and an auditor going-concern warning, underscoring the need for additional capital.